• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Aquestive Therapeutics Inc (NQ: AQST )

    4.760 -0.220 (-4.42%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Oct 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,407,981
    Open 4.980
    Bid (Size) 4.760 (25)
    Ask (Size) 4.920 (10)
    Prev. Close 4.980
    Today's Range 4.750 - 4.980
    52wk Range 1.251 - 6.230
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
    Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
    Via Benzinga
    Exposures Product Safety
    Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire

    Performance

    YTD
    +136.82%
    +136.82%
    1 Month
    +13.60%
    +13.60%
    3 Month
    +94.29%
    +94.29%
    6 Month
    +15.25%
    +15.25%
    1 Year
    +240.00%
    +240.00%

    More News

    Read More
    Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows
    Via Benzinga
    Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant™ (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm™ (epinephrine) Sublingual Film
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday
    Via Benzinga
    Coming FDA Approvals Could Send These 3 Drug Stocks Soaring
    Via InvestorPlace
    Exposures Product Safety
    Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
    From Aquestive Therapeutics, Inc.
    Via GlobeNewswire
    Why STAAR Surgical Shares Are Trading Higher By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    Lamb Weston Reports Weak Earnings, Joins Paragon 28, Resources Connection And Other Big Stocks Moving Lower On Thursday
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.